Will Korean bio stocks rebound as MSCI includes Celltrion, Viromed, HLB?
기사승인 2018.05.16 11:25:14
Marian Chu yjc@docdocdoc.co.kr
- 1PharmaPfizer feeling bittersweet over Korea’s biosimilars
- 2PharmaKainos Medicine starts developing treatment for multiple system atrophy
- 3PharmaSanofi gets nod to increase dosage for multiple sclerosis treatment
- 4Device/ICTRegulators raid Abbott Korea over rebate allegations
- 5Life scienceKUGH uses big data-based machine learning to predict type 2 diabetes
- 6PharmaAbbVie’s new hepatitis C treatment outpaces Gilead’s rival drugs
- 7PharmaPfizer’s lung cancer drug Xalkori threatened by new rivals
set_C1
